The ergoloid mesylate dihydroergotoxine: radioimmunoassay measurements on plasma and blood-pressure-lowering activity.
Dihydroergotoxine plasma concentrations determined using a newly developed radioimmunoassay method and corresponding blood-pressure-lowering effects have been measured in normotensive subjects after intravenous injection (0.6 mg) and administration of an oral solution (4.5 mg). Plasma concentrations in the range 0.2-1 ng/ml dihydroergotoxine produced clinically significant reductions of up to 15% in systolic and diastolic standing and supine blood pressures, while no significant changes occurred in pulse rate.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D004088:Dihydroergotoxine / Q000097:blood* / Q000494:pharmacology; D006801:Humans; D008297:Male; D011674:Pulse / Q000187:drug effects; D011863:Radioimmunoassay
D004088:Dihydroergotoxine